Shots:

• Teriparatide biosimilar is the first product developed under Mochida and Gedeon Richter license agreement and is expected to improve the QoL while reducing the financial burden of patients with osteoporosis
• Teriparatide BS Injection Kit 600μg is a novel biosimilar approved in Japan targeted for osteoporosis with a recommended dose of 20 μg SC once a day that enhances bone formation and improves bone structure
• It is a disposable kit enabled with a delivery device and can also be self-injected with the announcement of its expected launch at the National Health Insurance Price Listing

Click here to­ read full press release/ article | Ref: Mochida | Image: Behance